We are live on
!
Find out more
GPP
Great Point Partners Portfolio holdings
AUM
$435M
1-Year Est. Return
318.81%
This Fund
S&P 500
This Quarter
Est. Return
-4.71%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$477M
AUM Growth
-$7.14M
(-1.5%)
Cap. Flow
+$18.1M
Cap. Flow
% of AUM
3.8%
Top 10 Holdings %
Top 10 Hldgs %
55.56%
Holding
40
New
12
Increased
10
Reduced
5
Closed
10
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
FOLD
Amicus Therapeutics
FOLD
|
+$15.6M |
| 2 |
RPTX
Repare Therapeutics
RPTX
|
+$14.3M |
| 3 |
Dianthus Therapeutics
DNTH
|
+$12.8M |
| 4 |
Dyne Therapeutics
DYN
|
+$12.6M |
| 5 |
Kura Oncology
KURA
|
+$12.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Iovance Biotherapeutics
IOVA
|
+$29.4M |
| 2 |
CNST
Constellation Pharmaceuticals, Inc.
CNST
|
+$20.4M |
| 3 |
Lantheus
LNTH
|
+$13.9M |
| 4 |
Biogen
BIIB
|
+$12.9M |
| 5 |
XENT
Intersect ENT, Inc
XENT
|
+$11.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 91.3% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
InflaRx
IFRX
$250M
| $6.53M | 1.37% |
2,200,000
| – | – |
|
27
Rigel Pharmaceuticals
RIGL
$681M
| $6.51M | 1.37% |
+150,000
| New | +$5.66M |
|
28
CytomX Therapeutics
CTMX
$675M
| $6.33M | 1.33% |
+1,000,000
| New | +$7.79M |
|
29
Spyre Therapeutics
SYRE
$8.54B
| $6.26M | 1.31% |
36,000
+15,884
| +79% | +$2.89M |
|
|
VERV
30
DELISTED
Verve Therapeutics
VERV
| $2.11M | 0.44% |
+35,000
| New | +$1.45M |
|
31
Acadia Pharmaceuticals
ACAD
$4.43B
| – | – |
-311,217
| Closed | -$8.03M |
|
32
Geron
GERN
$828M
| – | – |
-2,610,000
| Closed | -$4.12M |
|
|
33
Iovance Biotherapeutics
IOVA
$1.82B
| – | – |
-930,000
| Closed | -$29.4M |
|
|
34
Lantheus
LNTH
$6.49B
| – | – |
-649,516
| Closed | -$13.9M |
|
35
Pulmonx
LUNG
$68.8M
| – | – |
-114,345
| Closed | -$5.23M |
|
|
RDHL
36
Redhill Biopharma
RDHL
$3.95M
| – | – |
-705
| Closed | -$5.16M |
|
|
YMAB
37
DELISTED
Y-mAbs Therapeutics
YMAB
| – | – |
-150,000
| Closed | -$4.54M |
|
|
NVRO
38
DELISTED
NEVRO CORP.
NVRO
| – | – |
-80,000
| Closed | -$11.2M |
|
|
RXDX
39
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| – | – |
-250,000
| Closed | -$4.57M |
|
|
CNST
40
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
| – | – |
-872,415
| Closed | -$20.4M |
|
Similar funds
GDS
JWM
SWG
SCP
VIM
VDBMI
ACG
TECP
Great Point Partners's Q2 2021 Portfolio in Review
As of Q2 2021, Great Point Partners held 40 positions worth $477M, down 1.5% from $484M the previous quarter. Its ten largest holdings account for 56% of the portfolio.
Great Point Partners deployed $18.1M of net new capital in Q2 2021, opening 12 new positions and adding to 10 existing holdings. Its largest new stake was Amicus Therapeutics: 1,600,000 shares worth $15.4M.
By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 94% a quarter earlier.
On the sell side, the largest reduction was Biogen, an estimated $12.9M trimmed.
- Great Point Partners's largest Q2 2021 buy was Amicus Therapeutics: 1,600,000 shares worth $15.4M.
- Great Point Partners added most to Travere Therapeutics in Q2 2021, an estimated $9.68M increase.
- Great Point Partners's biggest Q2 2021 reduction was Biogen, cutting an estimated $12.9M.
- Great Point Partners fully exited Iovance Biotherapeutics in Q2 2021, selling an estimated $29.4M.
- Great Point Partners's ten largest holdings make up 56% of its $477M portfolio in Q2 2021.
- Great Point Partners opened 12 new positions and closed 10 in Q2 2021.
- Great Point Partners's portfolio value fell 1.5% quarter-over-quarter to $477M.
Based on Great Point Partners's 13F filing for Q2 2021, filed 16 Aug 2021.